ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

No Thumbnail Available

Date

2022

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Description

Keywords

Citation

URI

http://hdl.handle.net/11727/8008

Collections

Tıp Fakültesi / Faculty of Medicine
Wos İndeksli Yayınlar Koleksiyonu
Wos Kapalı Erişimli Yayınlar

Endorsement

Review

Supplemented By

Referenced By